Key result
A pharmacist-led follow-up program was highly appreciated by patients with coronary heart disease, who reported increased medication knowledge and a greater feeling of safety.
Why the study?
How do patients with coronary heart disease experience a pharmacist-led follow-up program after hospital discharge?
How do patients with coronary heart disease experience a pharmacist-led follow-up program after hospital discharge?
A pharmacist-led follow-up program for patients with CHD after hospital discharge was highly appreciated by patients, improving their medication knowledge and feeling of safety.
Patients valued pharmacist-led CHD follow-up for greater medication knowledge and safety; leaves open whether programs improve outcomes in larger cohorts.
BACKGROUND: Coronary heart disease (CHD) is one of the leading causes of death worldwide. Scientific literature shows that prevention of CHD is inadequate. The clinical pharmacist's role in patient-centred care has been shown favourable in a large amount of studies, also in relation to reduction of risk factors related to CHD. We developed and piloted a pharmacist-led follow-up program for patients with established CHD after hospital discharge from a hospital in North Norway. The aim of the present study was to explore how participants in the follow-up program experienced the program with regard to four main topics; medication knowledge, feeling of safety and comfort with medications, the functionality of the program and the clinical pharmacist's role in the interdisciplinary team. METHODS: We performed semi-structured thematic interviews with four patients included in the program. After verbatim transcribing, we analysed the interviews using "qualitative content analyses" by Graneheim and Lundman. Trial registration http://www.clinicaltrials.gov: NCT01131715. RESULTS: All participants appreciated the follow-up program because their medication knowledge had increased, participation had made them feel safe, they were reassured about the appropriateness of their medications, and they had become more involved in their own medication. The participants reported that the program was well structured and the clinical pharmacist was said to be an important caretaker in the health-care system. The importance of collaboration between pharmacists and physicians, both in hospital and primary care, was emphasized. CONCLUSION: Our results indicate that the follow-up program was highly appreciated among the four participants included in this study. The results must be interpreted in the context of the health care system in Norway today. Here, few pharmacists are working in hospitals or in close relation to the general practitioners. In addition, physicians are short of time in order to supply appropriate medication information, both in hospital and primary care. Involving pharmacists in follow-up of patients with CHD seems to be highly appreciated among patients and may be a step towards improving patient care. The study is limited by the low number of participants.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2014) studied Coronary heart disease (n=4). Pharmacist-led follow-up program was evaluated on Patient experiences regarding medication knowledge, feeling of safety, program functionality, and the pharmacist's role. A pharmacist-led follow-up program was highly appreciated by patients with coronary heart disease, who reported increased medication knowledge and a greater feeling of safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: